In Brief: FDA reform
This article was originally published in The Tan Sheet
Executive Summary
FDA reform: At a May 12 briefing for House Commerce Committee staff, the Pharmaceutical Research & Manufacturers Association noted that one of its "14 points" for FDA reform is increased facilitation of Rx-to-OTC switches. The Biotechnology Industry Organization proposed that FDA consolidate its drug, medical device and biologics centers to create "consistent" regulation of finished products rather than processes...
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning